184 related articles for article (PubMed ID: 15608688)
1. Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPAR(gamma) fusion oncogene.
Lui WO; Foukakis T; Lidén J; Thoppe SR; Dwight T; Höög A; Zedenius J; Wallin G; Reimers M; Larsson C
Oncogene; 2005 Feb; 24(8):1467-76. PubMed ID: 15608688
[TBL] [Abstract][Full Text] [Related]
2. Is thyroid follicular cancer in Japanese caused by a specific t(2; 3)(q13; p25) translocation generating Pax8-PPAR gamma fusion mRNA?
Hibi Y; Nagaya T; Kambe F; Imai T; Funahashi H; Nakao A; Seo H
Endocr J; 2004 Jun; 51(3):361-6. PubMed ID: 15256783
[TBL] [Abstract][Full Text] [Related]
3. Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations.
Lacroix L; Lazar V; Michiels S; Ripoche H; Dessen P; Talbot M; Caillou B; Levillain JP; Schlumberger M; Bidart JM
Am J Pathol; 2005 Jul; 167(1):223-31. PubMed ID: 15972966
[TBL] [Abstract][Full Text] [Related]
4. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.
Nikiforova MN; Lynch RA; Biddinger PW; Alexander EK; Dorn GW; Tallini G; Kroll TG; Nikiforov YE
J Clin Endocrinol Metab; 2003 May; 88(5):2318-26. PubMed ID: 12727991
[TBL] [Abstract][Full Text] [Related]
5. Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation.
Giordano TJ; Au AY; Kuick R; Thomas DG; Rhodes DR; Wilhelm KG; Vinco M; Misek DE; Sanders D; Zhu Z; Ciampi R; Hanash S; Chinnaiyan A; Clifton-Bligh RJ; Robinson BG; Nikiforov YE; Koenig RJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1983-93. PubMed ID: 16609007
[TBL] [Abstract][Full Text] [Related]
6. Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas.
Cheung L; Messina M; Gill A; Clarkson A; Learoyd D; Delbridge L; Wentworth J; Philips J; Clifton-Bligh R; Robinson BG
J Clin Endocrinol Metab; 2003 Jan; 88(1):354-7. PubMed ID: 12519876
[TBL] [Abstract][Full Text] [Related]
7. A subset of the follicular variant of papillary thyroid carcinoma harbors the PAX8-PPARgamma translocation.
Castro P; Roque L; Magalhães J; Sobrinho-Simões M
Int J Surg Pathol; 2005 Jul; 13(3):235-8. PubMed ID: 16086077
[TBL] [Abstract][Full Text] [Related]
8. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas.
Marques AR; Espadinha C; Catarino AL; Moniz S; Pereira T; Sobrinho LG; Leite V
J Clin Endocrinol Metab; 2002 Aug; 87(8):3947-52. PubMed ID: 12161538
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic implications of the PAX8-PPARγ translocation in thyroid carcinomas-a TMA-based study of 226 cases.
Boos LA; Dettmer M; Schmitt A; Rudolph T; Steinert H; Moch H; Sobrinho-Simões M; Komminoth P; Perren A
Histopathology; 2013 Aug; 63(2):234-41. PubMed ID: 23738683
[TBL] [Abstract][Full Text] [Related]
10. [Oncogenes and thyroid tumors].
Lacroix L; Soria JC; Bidart JM; Schlumberger M
Bull Cancer; 2005 Jan; 92(1):37-43. PubMed ID: 15689324
[TBL] [Abstract][Full Text] [Related]
11. The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARgamma fusion.
Foukakis T; Au AY; Wallin G; Geli J; Forsberg L; Clifton-Bligh R; Robinson BG; Lui WO; Zedenius J; Larsson C
J Clin Endocrinol Metab; 2006 Mar; 91(3):1143-9. PubMed ID: 16352687
[TBL] [Abstract][Full Text] [Related]
12. Low frequency of PAX8-PPARγ rearrangement in follicular thyroid carcinomas in Japanese patients.
Mochizuki K; Kondo T; Oishi N; Tahara I; Inoue T; Kasai K; Nakazawa T; Okamoto T; Shibata N; Katoh R
Pathol Int; 2015 May; 65(5):250-3. PubMed ID: 25708358
[TBL] [Abstract][Full Text] [Related]
13. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected].
Kroll TG; Sarraf P; Pecciarini L; Chen CJ; Mueller E; Spiegelman BM; Fletcher JA
Science; 2000 Aug; 289(5483):1357-60. PubMed ID: 10958784
[TBL] [Abstract][Full Text] [Related]
14. PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues.
Lacroix L; Mian C; Barrier T; Talbot M; Caillou B; Schlumberger M; Bidart JM
Eur J Endocrinol; 2004 Sep; 151(3):367-74. PubMed ID: 15362967
[TBL] [Abstract][Full Text] [Related]
15. Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours.
Banito A; Pinto AE; Espadinha C; Marques AR; Leite V
Clin Endocrinol (Oxf); 2007 Nov; 67(5):706-11. PubMed ID: 17651453
[TBL] [Abstract][Full Text] [Related]
16. Analysis of RAS mutation and PAX8/PPARγ rearrangements in follicular-derived thyroid neoplasms in a Korean population: frequency and ultrasound findings.
Jeong SH; Hong HS; Kwak JJ; Lee EH
J Endocrinol Invest; 2015 Aug; 38(8):849-57. PubMed ID: 25999051
[TBL] [Abstract][Full Text] [Related]
17. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
Albarel F; Conte-Devolx B; Oliver C
Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
[TBL] [Abstract][Full Text] [Related]
18. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma.
Castro P; Rebocho AP; Soares RJ; Magalhães J; Roque L; Trovisco V; Vieira de Castro I; Cardoso-de-Oliveira M; Fonseca E; Soares P; Sobrinho-Simões M
J Clin Endocrinol Metab; 2006 Jan; 91(1):213-20. PubMed ID: 16219715
[TBL] [Abstract][Full Text] [Related]
19. Detection of PAX8/PPARG and RET/PTC rearrangements is feasible in routine air-dried fine needle aspiration smears.
Ferraz C; Rehfeld C; Krogdahl A; Precht Jensen EM; Bösenberg E; Narz F; Hegedüs L; Paschke R; Eszlinger M
Thyroid; 2012 Oct; 22(10):1025-30. PubMed ID: 23025542
[TBL] [Abstract][Full Text] [Related]
20. Identification of a paired box gene 8-peroxisome proliferator-activated receptor gamma (PAX8-PPARgamma) rearrangement mosaicism in a patient with an autonomous functioning follicular thyroid carcinoma bearing an activating mutation in the TSH receptor.
Lado-Abeal J; Celestino R; Bravo SB; Garcia-Rendueles ME; de la Calzada J; Castro I; Castro P; Espadinha C; Palos F; Soares P; Alvarez CV; Sobrinho-Simões M; Cameselle-Teijeiro J
Endocr Relat Cancer; 2010 Sep; 17(3):599-610. PubMed ID: 20427420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]